JP2023506454A5 - - Google Patents
Info
- Publication number
- JP2023506454A5 JP2023506454A5 JP2022535520A JP2022535520A JP2023506454A5 JP 2023506454 A5 JP2023506454 A5 JP 2023506454A5 JP 2022535520 A JP2022535520 A JP 2022535520A JP 2022535520 A JP2022535520 A JP 2022535520A JP 2023506454 A5 JP2023506454 A5 JP 2023506454A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- nos
- target
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947749P | 2019-12-13 | 2019-12-13 | |
| US62/947,749 | 2019-12-13 | ||
| PCT/US2020/064651 WO2021119516A1 (en) | 2019-12-13 | 2020-12-11 | Cytokine-based bioactivatable drugs and methods of uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506454A JP2023506454A (ja) | 2023-02-16 |
| JP2023506454A5 true JP2023506454A5 (https=) | 2023-12-19 |
Family
ID=76330652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535520A Pending JP2023506454A (ja) | 2019-12-13 | 2020-12-11 | サイトカインをベースとした生理活性化薬剤およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230093155A1 (https=) |
| EP (1) | EP4072593A4 (https=) |
| JP (1) | JP2023506454A (https=) |
| KR (1) | KR20220115611A (https=) |
| AU (1) | AU2020403148A1 (https=) |
| CA (1) | CA3164353A1 (https=) |
| MX (1) | MX2022007202A (https=) |
| WO (1) | WO2021119516A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| JP2023540629A (ja) * | 2020-09-16 | 2023-09-25 | ベイジーン リミテッド | インターロイキン１５構築物及び使用方法 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20230056336A1 (en) * | 2021-04-15 | 2023-02-23 | Kyverna Therapeutics, Inc. | Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| US20230201364A1 (en) * | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| WO2023281480A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| AU2022306974A1 (en) * | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| EP4366781A1 (en) * | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
| CA3257348A1 (en) * | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | INTERLEUKIN-2 PROPROTEINS AND THEIR USES |
| CA3258187A1 (en) * | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | INTERLEUKIN-2 PROPROTEINS AND THEIR USES |
| CN119790066A (zh) * | 2022-08-05 | 2025-04-08 | 舒泰神(加州)生物科技有限公司 | 一种新型IL-15R alpha Fc融合蛋白及其使用 |
| AU2023347072A1 (en) * | 2022-09-20 | 2025-01-02 | Currus Biologics Pty Ltd | Bispecific polypeptides and uses thereof |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| EP4695281A1 (en) * | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) * | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024238631A2 (en) * | 2023-05-15 | 2024-11-21 | Purdue Research Foundation | A cytokine-like propeptide gene therapy platform |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025217310A1 (en) * | 2024-04-10 | 2025-10-16 | Prolynx Llc | Pegylated il- 15 receptor alpha cytokines |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| CN120148681B (zh) * | 2025-02-17 | 2025-12-12 | 华中科技大学 | 一种基于虚拟图和多尺度特征的抗体偶联药物活性预测方法和系统 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006105338A2 (en) * | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| WO2016033509A1 (en) * | 2014-08-29 | 2016-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica |
| PL3235830T3 (pl) * | 2014-12-19 | 2020-12-14 | Jiangsu Hengrui Medicine Co., Ltd. | Kompleks białkowy interleukiny 15 i jego zastosowanie |
| CN109071667A (zh) * | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| MY201482A (en) * | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| KR102418437B1 (ko) * | 2017-12-08 | 2022-07-07 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| AU2019228381B2 (en) * | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| SG11202010163QA (en) * | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| MA52289A (fr) * | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| MX2020011552A (es) * | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| CN110437339B (zh) * | 2018-05-04 | 2021-08-13 | 免疫靶向有限公司 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| AU2019288484B2 (en) * | 2018-06-22 | 2024-06-20 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| WO2020123980A1 (en) * | 2018-12-14 | 2020-06-18 | Proviva Therapeutics (Hong Kong) Limited | Il-15 compositions and methods of use thereof |
| CA3141626A1 (en) * | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| EP3997115A4 (en) * | 2019-07-12 | 2023-11-22 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
-
2020
- 2020-12-11 MX MX2022007202A patent/MX2022007202A/es unknown
- 2020-12-11 KR KR1020227024242A patent/KR20220115611A/ko active Pending
- 2020-12-11 AU AU2020403148A patent/AU2020403148A1/en active Pending
- 2020-12-11 JP JP2022535520A patent/JP2023506454A/ja active Pending
- 2020-12-11 WO PCT/US2020/064651 patent/WO2021119516A1/en not_active Ceased
- 2020-12-11 CA CA3164353A patent/CA3164353A1/en active Pending
- 2020-12-11 EP EP20899199.2A patent/EP4072593A4/en active Pending
- 2020-12-11 US US17/784,305 patent/US20230093155A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506454A5 (https=) | ||
| JP7553504B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| ES2688035T3 (es) | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes | |
| JP7427286B2 (ja) | ＩＬ－２ＲβγＣ結合化合物 | |
| JP7427287B2 (ja) | 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 | |
| ES2676630T3 (es) | Control inmunogénico de tumores y células tumorales | |
| JP7755371B2 (ja) | 共通キメラ抗原受容体発現免疫細胞のためのターゲティングモジュールならびに癌、感染および自己免疫障害の処置における使用 | |
| CN113354739B (zh) | 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用 | |
| JP2021521822A5 (https=) | ||
| US11987609B2 (en) | Proteinaceous heterodimer and use thereof | |
| CN109734800B (zh) | 一种裂谷热病毒人源单克隆抗体及其应用 | |
| CN109265565B (zh) | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 | |
| CN114437218B (zh) | 靶向cd276的嵌合抗原受体以及包含其的免疫细胞 | |
| KR20210107747A (ko) | 항체 융합 단백질, 이의 제조 방법 및 이의 적용 | |
| CN113461825B (zh) | 一种抗pd-l2纳米抗体及其应用 | |
| AU2022232674A9 (en) | Anti-her2 antibody-immune agonist conjugate and applications thereof | |
| JP2023548861A (ja) | ＩＬ－２Ｒβγｃ結合化合物及びその使用 | |
| WO2022022709A1 (zh) | 一种SIRPα-Fc融合蛋白 | |
| JP2023524995A5 (https=) | ||
| KR20250166188A (ko) | Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법 | |
| CN116284430A (zh) | 靶向肿瘤的il15融合蛋白及其应用 | |
| WO2022100585A1 (zh) | 抗Her-2抗体-趋化因子融合蛋白及其制法和应用 | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| US20240190934A1 (en) | Engineered interleukin-10 and fusion proteins thereof | |
| US20250302875A1 (en) | TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMAL |